Cabot Corporation (NYSE:CBT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Cabot Corporation (NYSE:CBT) have been assigned an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $72.25.

A number of equities analysts have recently commented on CBT shares. UBS Group lifted their price objective on Cabot from $65.00 to $74.00 and gave the stock a “neutral” rating in a research note on Monday, January 12th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $81.00 price target on shares of Cabot in a research report on Thursday, January 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Cabot in a research report on Monday, December 29th. Zacks Research downgraded shares of Cabot from a “hold” rating to a “strong sell” rating in a research note on Friday, November 7th. Finally, Mizuho boosted their target price on shares of Cabot from $72.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 18th.

Cabot Price Performance

Shares of Cabot stock opened at $72.99 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $66.96 and a 200-day simple moving average of $71.91. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 12.14, a PEG ratio of 3.82 and a beta of 0.89. Cabot has a 1-year low of $58.33 and a 1-year high of $89.79.

Cabot (NYSE:CBT) last announced its earnings results on Monday, November 3rd. The specialty chemicals company reported $1.70 EPS for the quarter, missing the consensus estimate of $1.72 by ($0.02). Cabot had a return on equity of 24.55% and a net margin of 8.91%.The firm had revenue of $899.00 million during the quarter, compared to the consensus estimate of $967.02 million. During the same quarter last year, the business earned $1.80 EPS. The business’s revenue was down 10.2% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-7.00 EPS. On average, sell-side analysts expect that Cabot will post 7.57 earnings per share for the current year.

Cabot Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 12th. Stockholders of record on Friday, November 28th were issued a dividend of $0.45 per share. The ex-dividend date was Friday, November 28th. This represents a $1.80 annualized dividend and a dividend yield of 2.5%. Cabot’s payout ratio is presently 29.95%.

Institutional Investors Weigh In On Cabot

Several hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC increased its stake in Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after acquiring an additional 947 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Cabot by 32.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after acquiring an additional 108,645 shares during the period. Empowered Funds LLC grew its holdings in shares of Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock worth $2,341,000 after purchasing an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cabot by 3.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in shares of Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the period. Institutional investors own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.